PAMA brings huge changes to lab price testing, faces resistance from ACLA

PAMA brings huge changes to lab price testing, faces resistance from ACLA

The Protecting Access to Medicare Act (PAMA) of 2014 has surprised the industry with sweeping, potentially devastating cuts to how lab tests are reimbursed through Medicare, with a whole host of tests seeing cuts of over a third. The American Clinical Laboratory Association (ACLA) is fighting back with a lawsuit over the methodology of the Centers for Medicare and Medicaid’s (CMS) data collection in determining the new pricing scheme. The American Association for Clinical Chemistry (AACC) also weighs in, and asserts that labs will need to make some big changes if they want to survive.

  • by Bruce Carlson
  • August 28 2018


$77.8 Billion-Dollar IVD Market by 2023: New Report

$77.8 Billion-Dollar IVD Market by 2023: New Report

Drivers outweigh limiters when it comes to the IVD market, according to Kalorama Information's latest IVD report, the 11th edition. Test procedures are up and will be up, but cost-cutting form major payors is limiting marketing growth slightly faster than emergings can make up for it. This article highlights some of the key findings of the report.


$32 Billion-Dollar Market for Vaccines

$32 Billion-Dollar Market for Vaccines

The market, driven by new products and increased usage in emerging markets, grows to 32 billion. But not without challenges.